BGLC
BioNexus Gene Lab Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.60
P/S
0.43
EV/EBITDA
-0.63
DCF Value
$-9.07
FCF Yield
-71.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
14.8%
Operating Margin
-24.8%
Net Margin
-24.3%
ROE
-30.2%
ROA
-30.1%
ROIC
-32.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | $-709.0K | $-0.39 |
| Q2 2025 | $2.3M | $-616.2K | $-0.34 |
| Q1 2025 | $2.1M | $-623.3K | $-0.35 |
| Q4 2024 | $2.5M | $-348.3K | $-0.19 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
MY
Exchange
NASDAQ
Beta
2.31
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.